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with IMRT were considered (incidence 7%). Late G2 and G3 GU TOX 
were 6% vs 7% and 3% vs 3%, respectively. 
Conclusions: This study provides support for the use of WPRT in 
combination with HDSRT in the salvage setting in node-negative 
patients. Especially if delivered with modern IMRT techniques, WPRT 
did not result in any additional toxicity. 
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Purpose/Objective: Numerous authors have attempted to establish 
models to minimise rectal late effects following prostate 
radiotherapy, most using data from standard fractionation regimes 
with disagreement as to predictive dosimetric values. This study 
looked to identify predictive Biochemical Equivalent Dose (BED) 
volumes, applicable for any treatment regime, using various dose 
mapping techniques. 
Materials and Methods: We retrospectively analysed dose volume 
data for 172 prostate adenocarcinoma patients, median age 65.1 
(range 48.1-75.5), treated at a single centre between 2006 and 2009 
with radical radiotherapy. All patients received 3D_CRT or IMRT 
according to evolving practise with dose fractions as shown in the 
table.  
 
Fractionation 52.5Gy/20# 50Gy/16# 74Gy/37# 60Gy/20# 57Gy/19# 
Planning 3D-CRT 3D-CRT IMRT IMRT IMRT 
Number 11 64 9 7 81 
 
Rectal dose-volume histograms (DVH) and dose-surface histograms 
(DVS) were calculated for each patient using standard rectal 
contouring (ano-rectal to recto-sigmoid junction) all performed or 
reviewed by the author. In addition distribution of dose to the latitude 
of the rectum was examined by converting the rectal surface dose 
into a 2D structure. Dose was converted into a BED using an 
alpha/beta ratio of 3 for the rectum. 
Each patient completed a LENT-SOMA questionnaire to assess late 
rectal toxicity. For this study answers regarding issue with 
constipation or diarrhoea were not considered as this was not felt to 
represent true late rectal toxicity alone. Partition analysis was 
performed for all data and for IMRT alone to establish if there was a 
BED and volume for any given mapping technique that was statistically 
significant in predicting late rectal toxicity (score ≥2).  
Results: Partition analysis from 0-100% of volume was performed at 
BED levels of 120Gy, 110Gy, 100Gy, 90Gy, 80Gy, 70Gy and 60Gy. At all 
of these doses there was no percentage volume of rectum receiving a 
given dose that was predictive for the development of late rectal 
toxicity regardless of dose mapping method and radiotherapy 
technique used.  
Conclusions: This study does not support the hypothesis that 
incidence of toxicity significantly increases above threshold 
dose/volumes using BED. This conflicts with previous studies looking 
at dose volume in standard 2Gy per fraction and others looking at the 
use of Equivalent Uniform Dose to normalise data from varying 
fractionation regimes. The use of lateral dose distribution has not 
been shown to have any additional predictive power over conventional 
dose mapping. This may in part be due to unaccounted for movement 
of the rectum during treatment comprising dose mapping data. 
Further ongoing study is attempting to quantify this degree of intra-
treatment movement and will be reported when available. 
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Purpose/Objective: The aim of the present study was to investigate 
the diagnostic gain in the detection of lymph node (LN) metastases by 
means of immunohistochemical (IHC) staining for pankeratin as 
compared to the routine histopathological evaluation. In addition, E-
Cadherin (ECad) expression was investigated within the concept of 
epithelial mesenchymal plasticity. 
Materials and Methods: Forty patients with a risk ≥10% but <35% for 
LN metastases (Partin tables) who were N0 at contrast-enhanced CT-
scan and did not receive any prior treatment were included in the 
study. They all underwent a superextended LND followed by radical 
prostatectomy (RP). All LN (n=838) were completely serially sectioned 
at 300µm and stained for pankeratin (n=4498), in addition to one 
central H&E-stained section per LN. Disease positivity was defined as 
the presence of any metastatic deposits in a LN and classified as 
follows: Macro+ (> 2mm), micro+ (<2 mm but >0.2 mm) and ITC (< 
0.2mm). ECad staining was performed on the diagnostic biopsies 
(n=36), RP specimens (n=39) and on the pankeratin-positive LN 
sections. Staining intensity was scored as negative/weak (1), 
moderate (2) or strong (3) and the staining pattern as inhomgeneous 
(0) or homogeneous (1). In case of staining heterogeneity, the most 
prevalent staining intensity was scored (Table 1). 
Results: Sixteen out of 40 (40%) patients were found to be node-
positive (N1) after routine H&E analysis. More specifically, 44 (5.3%) 
affected LN were found in which 25 Macro+, 19 micro+ and 9 ITC were 
detected. Step-section IHC analysis with pankeratin revealed 
metastatic disease in 2 patients that were previously N0. In each of 
these patients 1 affected LN was found, i.e. 1 LN harbouring a micro+ 
as well as a group of ITC and the other one harbouring only 1 group of 
ITC. Four additional affected LN in which micro+ and/or ITC were 
detected, were found in 3 patients that were already N1. Altogether, 
this detailed IHC analysis resulted in 50 (6.0%) affected LN, i.e. 25 
Macro+, 24 micro+ and 17 groups of ITC, that were found in 18/40 
(45%) patients. The majority of biopsies (92%) and RP specimens (79%) 
showed strong, homogeneous ECad expression. In contrast, ECad 
expression in the LN was found to be weak in about 60% of all cases. 
While the ECad staining pattern in the ITC and micro+ was mainly 
homogenous, the Macro+ showed a much more heterogeneous pattern 
(Pearson Chi-square p <0.0001). 
 
 
Conclusions: IHC analysis of serially sectioned LN increased the 
detection rate of pelvic LN metastases only marginally. This labour-
intensive and expensive procedure cannot be recommended as long as 
the clinical relevance of micrometastatic disease and ITC is not 
proven. Indicative to this could be the difference in ECad staining 
homogeneity between the ITC/micro+ and Macro+. The different 
staining intensities in the Macro+ may indicate an ongoing 
mesenchymal epithelial transition, presumed to be a mechanism for 
metastatic colonisation [Wells A 2008].  
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Purpose/Objective: Whole-pelvis radiotherapy (WPRT) may have a 
role both in the adjuvant (ADV) and salvage (SALV) setting after 
radical prostatectomy (RP) for prostate cancer (PCa). Aim of this 
analysis was to investigate a possible role of WPRT in increasing the 
risk of radiation-induced second neoplasms (2ndNPL) in the post-
prostatectomy setting. 
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Materials and Methods: From 1993 to 2007, 953 patients (median age 
65 years) underwent ADV (n=685) or SALV (n=268) RT with non 
conformal (n=169), 3DCRT (n=658) or IMRT (n=20) technique at 1.80 
Gy/fraction, at a median RT dose of 70.2 Gy, or moderately 
hypofractionated (median 28 fractions) Tomotherapy (n=106) to a 
median 2-Gy equivalent (EQD2, a/b=3) dose of 70 Gy. WPRT was 
delivered to 282 patients at a median of 50 Gy. The median follow-up 
(FU) of pts treated with prostatic bed (PB) only RT was longer (110 vs 
85 months) as compared to the WPRT+PB group.  
Results: After a median FU of 103 months, actuarial 10-year overall 
survival (OS) was 86%. A 2ndNPL arose in 101 patients after a median 
of 46 months from RT (44/101 after >5 years). Thirty-two were 
INFIELD and 69 were OUTFIELD. The 10-year overall risk of 2ndNPL 
was 14% vs 9% (p=0.10) for pts receiving PB only or WPRT+PB, 
respectively (4% vs 2%, p=0.17, for INFIELD and 9% vs 6%, p=0.33, for 
OUTFIELD). Of note, the 10-year risk of 2ndNPL was significantly 
higher (17% vs 11%, p=0.02) in patients experiencing any (acute or 
late) GU toxicity Grade ≥2. Multivariate analysis, which indicated the 
independent predictive role of age >65 year in all subgroups, 
confirmed Grade ≥2 GU toxicity as a significant predictor of the risk of 
overall (HR 2.15, p=0.04) and OUTFIELD (HR 2.10, p=0.04), but not 
INFIELD 2ndNPL. When the analysis was limited to 2ndNPL onset after 
>5 year from RT, diabetes emerged as the only independent predictor 
of overall 2ndNPL (HR 2.19, p=0.048) and age >65 that of OUTFIELD 
ones (HR 1.08, p=0.02), while no factors independently predicted 
INFIELD 2ndNPL (n=13). Overall, 123 pts died, 53 owing to PCa 
progression, 34 to a 2ndNPL and 36 to non neoplastic causes. The 10-
year risk of death was quite similar in pts experiencing a clinical 
relapse of PCa or an INFIELD or OUTFIELD 2ndNPL (40% vs 31% vs 37%, 
respectively, p=0.48) and significantly higher than that (6%) of pts 
bNEDs or with a PSA failure only after RT. Importantly, no role 
emerged for RT dose, technique or fractionation. 
Conclusions: Although preliminary, this study suggests that the 
impact of treating larger volumes with WPRT may be not significant, 
in contrast with the hypothesis of a proportionally higher incidence of 
2ndNPL with the increase of body integral dose. The correlation which 
emerged between GU toxicity and the risk of 2ndNPL deserves further 
investigation.  
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Purpose/Objective: Purpose of this study is to analyze outcomes and 
pre-treatment prognostic factors in high-risk prostate cancer patients 
with initial PSA > 20 ng/mL, treated with high-dose External-Beam 
Radiotherapy (EBRT) and androgen-deprivation therapy (ADT) in a 
single institution. 
Materials and Methods: Between March 2003 and December 2011, 155 
consecutive high-risk prostate cancer patients a) presenting with 
pretreatment PSA level > 20 ng/mL, b) treated with definitive EBRT 
and c) with a minimum follow-up of 24 months were included in this 
retrospective analysis. Phoenix definition was used to define 
biochemical control. Multivariate analysis was performed to 
determine the independent prognostic impact of pre-treatment 
clinical factors (T stage, PSA and Gleason Score [GS]) on clinical 
outcomes (biochemical Disease-Free Survival [bDFS], Distant 
Metastasis Free Survival [DMFS], Cancer-Specific Survival [CSS], 
Overall Survival [OS]). 
Results:  
 
At a median follow-up of 62 months, actuarial bDFS, DMFS, CSS and OS 
at 5 years were 64.8%, 85.2%, 95.8%, and 94.4%, respectively. On 
multivariate analysis, only GS was significantly associated with three 
clinical endpoints (bDFS: HR 1.6; p=0.022, CSS: HR 4.27, p=0.044, OS: 
HR 2.6;p=0.038). Pre-treatment zenith PSA (zPSA) was associated only 
with bDFS (HR 1.87; p=0.027). 
Conclusions: Patients with 'high' PSAl evels (>20 ng/mL) or 'ultra-high' 
PSA levels (> 50 ng/mL) showed favorable clinical outcomes, 
supporting thus the role of local radiotherapy as primary therapy in 
combination with long-term ADT in patients with high PSA levels at 
diagnosis. As GS of 8-10 resulted to be the strongest predictor of 
outcome, a subgroup of patients at worse prognosis might be early 
identified, since these patients represent the ideal candidates for 
more tailored and aggressive therapies in future trials. 
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Purpose/Objective: Neo-adjuvant chemotherapy (nCT) has known 
survival benefit in the treatment of MIBC. Favourable response is 
associated with improved outcome and identifies those who may 
benefit from bladder preservation with radical radiotherapy. 
Conventionally response assessment is with cystoscopy. We report on 
the use of DW-MRI as a potential non-invasive alternative means of 
assessment and as a predictor of nCT sensitivity.  
Materials and Methods: 19 patients with confirmed MIBC suitable for 
nCT were recruited prospectively to an ethics approved protocol. DW-
MRI was performed on a 1.5T system using b-values 0,50,100,250,500 
and 750s/mm2 prior to and on completion of nCT. Tumour was drawn 
on the 750s/mm2 image and transferred onto the corresponding ADC 
map to record mean values. Following final DW-MRI patients 
proceeded to cystoscopy + biopsy. Association between nCT 
sensitivity, pre-treatment ADC, post-treatment ADC and change of 
ADC (ΔADC) was analysed. 
Results: 12 patients achieved pathological complete response, 6 
achieved partial response and 1 progressed following nCT (as assessed 
on cystoscopy and T2-weighted MRI). In 15 patients tumour was 
identified on pre-nCT DW-image. 4 patients had no measurable 
disease on pre-nCT MRI. Baseline tumour median ADC was 1.3x10-
3mm2/s (range 0.7-2.7x10-3mm2/s). 
Complete response was associated with a significant increase in 
median ADC from 1.3x10-3mm2/s (range 0.7-2.7x10-3mm2/s) to 2.2x10-
3mm2/s (range 1.9-3.2x10-3mm2/s) (p=0.036). Change in mean ΔADC 
was significantly greater in complete responders compared to 
incomplete responders; responders median ΔADC 1.1x10-3 mm2/s, 
range 0.6-1.41x10-3mm2/s; incomplete responders median ΔADC 
0.1x10-3mm2/s, range 0.03-0.3x10-3mm2/s (p=0.034). 
Pre-treatment ADC was not predictive of response to nCT.  
